Please login to the form below

Zealand Pharma

This page shows the latest Zealand Pharma news and features for those working in and with pharma, biotech and healthcare.

Boehringer bolsters NASH pipeline with $870m Yuhan deal

therapies. Boehringer is a diabetes specialist and already has a dual GLP-1 and glucagon agonist, partnered with Zealand Pharma, in phase 1b testing. ... later this year, as well as a drug candidates for the disease covered by its recently expanded $201m

Latest news

Sanofi loses lead on diabetes combo IGlarLixi after FDA delay

The FDA has asked for more information on Sanofi and Zealand Pharma's IGlarLixi combination drug for diabetes, giving a rival drug from Novo Nordisk a chance to be first to
Sanofi uses priority review voucher for diabetes combo

The French pharma group paid $245m for the voucher - which cuts four months of the FDA's usual review time - in a deal with Retrophin earlier this year. ... Lixisenatide is a once-daily GLP-1 agonist that was invented by Zealand Pharma and has been sold
Boehringer switches diabetes candidate in Zealand collaboration

Zealand Pharma said potential choices include medicines that require once-weekly dosing, something that could give it an edge over the current leading GLP-1 agonist, Novo Nordisk's Victoza (liraglutide), ... Zealand has existing interests in the field of
Sanofi receives EU approvals for diabetes and cancer drugs

Lyxumia's approval is good news too for the drug's inventors Zealand Pharma who signed a deal with Sanofi to further develop the drug. ... Zealand also said it is eligible to receive remaining development, regulatory and sales milestone payments of up to
Hybrigenics appoints Dr Alain Munoz

As well as his position at Hybrigenics, Dr Munoz is also a board member of several biotechnology companies including Novagali Pharma and Zealand Pharma.

More from news
Approximately 1 fully matching, plus 13 partially matching documents found.

Latest Intelligence

Deal Watch October 2018

Acquisition. $244m. Zealand/. Royalty Pharma. Royalty streams and milestones for Soliqua 100/33/. ... So two opportunities here – acquisition of animal health products and out-licensing to Bayer’s pharma business.
Deal Watch table for July 2014

For an indepth analysis of these deals, read'Pharma deals during July 2014'. ... 635. Zealand Pharma/ Boehringer Ingelheim. R&D collaboration. Peptide discovery collaboration with cardio-metabolic focus.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

David Horn Solomon takes the helm of Akari Therapeutics

David has a strong track record of leading phase II stage companies like Akari, most notably at Zealand Pharma where he led the development of lixisenatide, which is now commercialised by ... Sanofi.”. His other roles have included CEO at Bionor Pharma
Glythera appoints Dr Mike Owen

Owen is also currently a director of Avacata plc, Blink Biomedical SAS, GammDelta Therapeutics, Ossianix Inc, ReNeuron plc and Zealand Pharma A/S. ... pipeline and building strategic partnerships with large pharma.”.
Bionor names executive management team additions

He has extensive experience as head of operation in public and private research intensive organisations and most recently served as director and general counsel to the management at Zealand Pharma. ... Rolstead has over 15 years of experience and has
Zealand announces management changes

Zealand Pharma is set to make a series of restructuring changes that will shake-up a number of positions at the firm. . ... The R&D arm of Zealand will be split into two parts, each with direct representation in management, while investor relations and
Zealand's Arvind Hundal steps down as chief business officer

She leaves after five years with the Danish biotech company. Dr Arvind Hundal has left Danish biotech company Zealand Pharma to pursue other opportunities. . ... served as a member of AstraZeneca's strategic planning business development organisation

More from appointments
Approximately 5 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Client Services Director – London or Home Based – Medical Commun...: Highly Competitive Salary, Bonus &Benefits

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

Editor & Senior Editor - Medical Communications - Home Based: Highly Competitive Salary, Bonus &Benefits

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Medical Writer, Senior Medical Writer, Principal Medical Writer,...: Highly Competitive Salary, Bonus &Benefits

Account Management: Competitive Salary Offered

Senior Account Director & Associate Director - Healthcare Ad...: Highly Competitive Salary, Bonus &Benefits

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Senior Content Editor - Biotechnology: Salary TBC

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

PMHub

Add my company

Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story: How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?: The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19: The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...